

Robert Greene Sterne Edward J. Kessler Jorge A. Goldstein Robert W. Esmond Michele A. Cimbala Michael B. Ray Robert E. Sokohl Michael O. Lee Steven R. Ludwig John M. Covert Linda E. Alcorn Robert C. Millonia Donald J. Featherstone Timothy J. Shea, Jr Michael V. Messinger

Judith U. Kim Patrick E. Garrett Jeffrey T. Helvey Heidi L. Kraus Eldora L. Ellison Thomas C. Fiala Donald R. Banowit Peter A. Jackman Jeffrey S. Weaver Kendrick P. Patterson Vincent L. Capuano Brian J. Del Buono Virgil Lee Beaston Theodore A. Wood Elizabeth J. Haanes Joseph S. Ostroff Frank R. Cottingham Rae Lynn P. Guest

Daniel A. Klein Jason D. Fisenberg Michael D. Specht Tracy L. Muller Jon E. Wright LuAnne M. DeSantis Ann E. Summerfield Helene C Carlson Cynthia M. Bouchez Timothy A. Doyle Gaby L. Longsworth Lori A. Gordon Nicole D. Dretar Ted J. Ebersole Laura A. Vogel Bryan S. Wade Aaron L. Schwartz Shannon A. Carroll\*

Wesley W. Jones\* Matthew E. Kelley\* Michelle K. Holoubek\* Marsha A. Rose\*

Registered Patent Agents Nancy J. Leith Matthew J. Dowd Katrina Yujian Pei Quach Bryan L. Skelton Robert A. Schwartzman Teresa A. Colella Victoria S. Rutherford Simon J. Elliott Julie A. Heider Mita Mukherjee Scott M. Woodhouse

Christopher J. Walsh Liliana Di Nola-Baron Peter A. Socarras Jeffrey Mills Danielle L. Letting

Of Counsel Kenneth C. Bass III Marvin C. Guthrie

\*Admitted only in Maryland \* Admitted only in Virginia Practice Limited to Federal Agencies

December 16, 2005

WRITER'S DIRECT NUMBER: (202) 772-8637 INTERNET ADDRESS: KARENM@SKGF.COM

Art Unit 1645

Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

Attn: Mail Stop Amendment

Re:

U.S. Utility Patent Application

Application No. 10/623,813; Filed: July 22, 2003 De novo DNA Cytosine Methyltransferase Genes, Polypeptides and Uses Thereof

Inventors:

LI et al.

Our Ref:

0609.4560003/KRM/DJN

Sir:

Transmitted herewith for appropriate action are the following documents:

- 1. Preliminary Amendment Under 37 C.F.R. § 1.115- with corrected first page; and
- 2. Return postcard.

The Preliminary Amendment submitted on November 23, 2005 had errors on the cover page captioning the incorrect application serial number and title. The Preliminary Amendment submitted herewith is being submitted with a corrected first page. It is respectfully requested that the Preliminary Amendment filed herewith be accepted as a replacement to the Preliminary Amendment filed on November 23, 2005.

It is respectfully requested that the attached postcard be stamped with the date of filing of these documents, and that it be returned to our courier. In the event that extensions of time are necessary to prevent abandonment of this patent application, then such extensions of time are hereby petitioned.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

Kauer R. Marton 103 Karen R. Markowicz Agent for Applicants

Registration No. 36,351

KRM/DJN:dbi Enclosures

474953 1.DOC

Sterne, Kessler, Goldstein & Fox P.L.C.: 1100 New York Avenue, NW: Washington, DC 20005: 202.371.2600 f 202.371.2540: www.skgf.com

## OEC 16 1005 EN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Li et al.

Appl. No.: 10/623,813

flication of:

Filed: July 22, 2003

For: De Novo DNA Cytosine

Methyltransferase Genes, Polypeptides and Uses Thereof Confirmation No.: 2332

Art Unit: 1645

Examiner: Harris, Alana M.

Atty. Docket: 0609.4560003/KRM/DJN

## Preliminary Amendment Under 37 C.F.R. § 1.115

Mail Stop Amendment

Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

Sir:

In advance of prosecution, Applicants submit the following amendments and remarks. This Preliminary Amendment is provided in the following format:

- (A) Each section begins on a separate sheet;
- (B) Starting on a separate sheet, amendments to the specification by presenting replacement paragraphs marked up to show changes made;
- (C) Starting on a separate sheet, a complete listing of all of the claims:
  - in ascending order;
  - with status identifiers; and
  - with markings in the currently amended claims;
- (D) Starting on a separate sheet, the Remarks.

It is not believed that extensions of time or fees for net addition of claims are required beyond those that may otherwise be provided for in documents accompanying this paper. However, if additional extensions of time are necessary to prevent

abandonment of this application, then such extensions of time are hereby petitioned under 37 C.F.R. § 1.136(a), and any fees required therefor (including fees for net addition of claims) are hereby authorized to be charged to our Deposit Account No. 19-0036.